Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates

• Published in: International journal of molecular sciences Vol. 23; no. 9; p. 5071
• Main Authors: Schuster, Sabine, Juhász, Éva, Halmos, Gábor, Neundorf, Ines, Gennari, Cesare, Mező, Gábor
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 03.05.2022; MDPI
• Subjects: Antigens; Antiproliferatives; Cathepsin B; Conjugates; Cytotoxicity; Daunorubicin; Drug delivery; drug delivery system; Drug delivery systems; Drugs; FDA approval; Gonadotropin-releasing hormone; Gonadotropins; Homing devices; Lysosomes; Ovarian cancer; Paclitaxel; Pancreatic cancer; peptide-drug conjugates; Peptides; Pituitary (anterior); targeted cancer therapy; Tumors; paclitaxel; targeted cancer therapy; antitumor activity; cathepsin B; drug delivery system; gonadotropin releasing hormone; peptide-drug conjugates; SMDC; daunorubicin
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23095071

The human gonadotropin releasing hormone (GnRH-I) and its sea lamprey analogue GnRH-III specifically bind to GnRH receptors on cancer cells and can be used as targeting moieties for targeted tumor therapy. Considering that the selective release of drugs in cancer cells is of high relevance, we were encouraged to develop cleavable, self-immolative GnRH-III-drug conjugates which consist of a -aminobenzyloxycarbonlyl (PABC) spacer between a cathepsin B-cleavable dipeptide (Val-Ala, Val-Cit) and the classical anticancer drugs daunorubicin (Dau) and paclitaxel (PTX). Alongside these compounds, non-cleavable GnRH-III-drug conjugates were also synthesized, and all compounds were analyzed for their antiproliferative activity. The cleavable GnRH-III bioconjugates revealed a growth inhibitory effect on GnRH receptor-expressing A2780 ovarian cancer cells, while their activity was reduced on Panc-1 pancreatic cancer cells exhibiting a lower GnRH receptor level. Moreover, the antiproliferative activity of the non-cleavable counterparts was strongly reduced. Additionally, the efficient cleavage of the Val-Ala linker and the subsequent release of the drugs could be verified by lysosomal degradation studies, while radioligand binding studies ensured that the GnRH-III-drug conjugates bound to the GnRH receptor with high affinity. Our results underline the high value of GnRH-III-based homing devices and the application of cathepsin B-cleavable linker systems for the development of small molecule drug conjugates (SMDCs).